Abbott Laboratories (NYSE: ABT) has reported E.P.S. of $0.94 for its third fiscal quarter (ending September 30) versus $0.82 for the same period a year ago — an increase of 15%. However, this performance was $-0.26 short of the consensus estimate of $1.20. E.P.S. were $3.30 for the latest four quarters through September 30 versus $2.95 for the same period a year ago — an increase of 12%.
Recent Price Action
On 10/16/24, Abbott Laboratories (NYSE: ABT) stock increased 1.5%, closing at $117.82. Moreover, trading volume in this advance was unusually high at 156% of normal. The stock has performed in line with the market over the last nine months and has risen 2.8% during the last week.
Current PriceTarget Research Rating
ABT is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Abbott Laboratories has a current Value Trend Rating of D (Negative). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Abbott Laboratories has a neutral Power Rating of 42 but a poor Appreciation Score of 22, leading to the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment